Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Average PT from Analysts

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been assigned an average rating of “Buy” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $23.00.

Several analysts recently commented on AURA shares. Cowen reiterated a “buy” rating on shares of Aura Biosciences in a research report on Friday. HC Wainwright upped their target price on shares of Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday. BTIG Research raised their price target on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday. JMP Securities upped their price objective on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, September 13th. Finally, Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th.

Insider Transactions at Aura Biosciences

In related news, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the sale, the chief technology officer now owns 121,132 shares in the company, valued at $1,193,150.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Aura Biosciences news, insider Los Pinos Elisabet De sold 24,992 shares of the business’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.04, for a total transaction of $300,903.68. Following the sale, the insider now directly owns 329,847 shares in the company, valued at approximately $3,971,357.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Mark Plavsic sold 7,383 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the transaction, the chief technology officer now directly owns 121,132 shares in the company, valued at approximately $1,193,150.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.40% of the company’s stock.

Institutional Trading of Aura Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. Long Focus Capital Management LLC lifted its position in shares of Aura Biosciences by 113.4% during the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after acquiring an additional 561,766 shares during the period. Regency Capital Management Inc. DE boosted its position in Aura Biosciences by 11.4% during the first quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company’s stock worth $6,163,000 after purchasing an additional 80,162 shares in the last quarter. Levin Capital Strategies L.P. grew its holdings in Aura Biosciences by 194.5% in the second quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock valued at $2,476,000 after purchasing an additional 216,266 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Aura Biosciences by 20.0% in the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock valued at $1,892,000 after buying an additional 41,711 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Aura Biosciences by 51.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after buying an additional 48,549 shares during the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Stock Performance

Aura Biosciences stock opened at $11.74 on Friday. The company has a market capitalization of $581.63 million, a P/E ratio of -6.31 and a beta of 0.37. Aura Biosciences has a fifty-two week low of $5.99 and a fifty-two week high of $12.38. The stock has a 50-day simple moving average of $8.66 and a 200-day simple moving average of $8.07.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.04. As a group, analysts forecast that Aura Biosciences will post -1.7 earnings per share for the current year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.